Goldstein: Expect More Litigation in Wake of Myriad Gene Patent Decision

more+
less-
June 13 (Bloomberg Law) -- Tom Goldstein, partner at Goldstein & Russell, PC and founder of SCOTUSblog, talks with Bloomberg Law's Lee Pacchia about the United States Supreme Court's decision in the Association for Molecular Pathology v. Myriad Genetics, Inc. case. At issue was whether patents may be granted on parts of the human body. He also explores whether Justice Scalia's concurrence raises doubts whether he believes in molecular biology, and where patent litigation will head in the wake of the decision. Bloomberg Law is a See more +
June 13 (Bloomberg Law) -- Tom Goldstein, partner at Goldstein & Russell, PC and founder of SCOTUSblog, talks with Bloomberg Law's Lee Pacchia about the United States Supreme Court's decision in the Association for Molecular Pathology v. Myriad Genetics, Inc. case. At issue was whether patents may be granted on parts of the human body. He also explores whether Justice Scalia's concurrence raises doubts whether he believes in molecular biology, and where patent litigation will head in the wake of the decision. Bloomberg Law is a sponsor of SCOTUSblog. See less -

Embed Video

Copy

Topics:  AMP v Myriad, Gene Patenting, Human Genes, Myriad, Patents

Published In: Constitutional Law Updates, Elections & Politics Updates, Intellectual Property Updates, Science, Computers & Technology Updates

DISCLAIMER: Because of the generality of this update, the information provided herein may not be applicable in all situations and should not be acted upon without specific legal advice based on particular situations.

© Bloomberg Law | Attorney Advertising

CONNECT

Bloomberg Law┬« has revolutionized the legal research industry by providing the first system that... View Profile »


Follow Bloomberg Law:

Reporters on Deadline